MSL
FOLD

Mackay Shields LLC’s Amicus Therapeutics FOLD Stock Holding History

Mackay Shields LLC’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-88,705
Closed -$877K – 936
2021
Q1 		$877K Sell
88,705
-58,101
-40% -$899K 0.01% 1027
2020
Q4 		$3.39M Sell
146,806
-17,600
-11% -$360K 0.02% 617
2020
Q3 		$2.32M Sell
164,406
-39,400
-19% -$574K 0.02% 727
2020
Q2 		$3.07M Sell
203,806
-45,200
-18% -$551K 0.02% 572
2020
Q1 		$2.3M Buy
249,006
+20,900
+9% +$199K 0.02% 612
2019
Q4 		$2.22M Buy
228,106
+5,500
+2% +$50.3K 0.02% 833
2019
Q3 		$1.78M Buy
222,606
+12,100
+6% +$131K 0.01% 939
2019
Q2 		$2.63M Buy
210,506
+135,601
+181% +$1.72M 0.02% 793
2019
Q1 		$1.02M Buy
74,905
+800
+1% +$9.77K 0.01% 993
2018
Q4 		$710K Buy
74,105
+5,473
+8% +$60.2K 0.01% 1045
2018
Q3 		$830K Buy
68,632
+4,300
+7% +$60.1K 0.01% 919
2018
Q2 		$1M Sell
64,332
-1,700
-3% -$25.7K 0.01% 947
2018
Q1 		$993K Buy
+66,032
New +$1M 0.01% 981

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackay Shields LLC's FOLD Position: Q2 2021 in Review

Mackay Shields LLC sold out of Amicus Therapeutics (FOLD) in Q2 2021, closing a stake of 88,705 shares — an estimated $877K sold.

Mackay Shields LLC first reported a position in FOLD in Q1 2018 and held it in 13 quarters. The position peaked at $3.39M in Q4 2020. 234 funds tracked by Wall St. Rank hold FOLD as of Q2 2021.

  • Mackay Shields LLC reported no remaining Amicus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 88,705 Amicus Therapeutics shares in Q2 2021, an estimated $877K.
  • Mackay Shields LLC first reported a position in Amicus Therapeutics in Q1 2018 and held it in 13 quarters.
  • Mackay Shields LLC's Amicus Therapeutics position peaked at $3.39M in Q4 2020.
  • 234 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.